Tesamorelin for Skin: GH Axis Effects on Dermal Layers
What's breaking down
The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.
Why Tesamorelin might help you
- Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.
How these fit together
Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.
- Tesamorelin → GH axis / visceral fat
What the evidence actually shows
This is a count of what is in this ledger — not a claim about all research worldwide.
- Scientific sources catalogued (PubMed, trials, reviews): 3
- Claims tagged human evidence: 2
- Claims tagged preclinical (animal/lab): 0
- Claims tagged anecdotal: 2
- Reddit posts catalogued: 1
- X posts catalogued: 1
- Other anecdote sources (YouTube, Instagram, etc.): 0
- Total sources in chain: 5
Quantified confidence (this ledger): 0.35 / 1.00 — low–moderate — mostly preclinical
Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.
What scientists say
Tesamorelin Peptide | Benefits, Safety, & Buying Advice (source s1)
Notes absence of direct skin studies and points to GH/IGF literature.
Evidence type: Published research.
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat (source s2)
Pooled phase-3 data on visceral fat; no skin endpoints reported.
Evidence type: Tagged human evidence in this ledger — check sample size and design.
Pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials (source s3)
Confirms human trial scale and primary outcome.
Evidence type: Tagged human evidence in this ledger — check sample size and design.
What people say on Reddit
Tesamorelin and skin : r/Peptides — Reddit, r/Peptides (source s4)
Example of anecdotal skin reports.
What people say on X
Peptide Confessions post on tesamorelin observations — X (source s5)
X anecdote on skin tightness.
---
Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.
Evidence ledger 6 · tier-ranked · API
1 more ranked claim
Model review1 contributions · 1 modelExpand the recursive review layer
/api/articles/tesamorelin-skin/contributionsAsk this article · 8 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.